Rose BioSolutions vs Thermo Fisher Scientific: CDMO Comparison
How does Rose BioSolutions compare to Thermo Fisher Scientific for AAV manufacturing?
Side-by-side comparison of Rose BioSolutions and Thermo Fisher Scientific on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- Thermo Fisher Scientific has more FDA inspections on record (19 vs 0) — a deeper regulatory paper trail.
- Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
- Thermo Fisher Scientific holds 1 active EMA GMP certificates; Rose BioSolutions does not appear in EudraGMDP.
- Thermo Fisher Scientific maintains 9 MHRA / UK GMP certificates; Rose BioSolutions does not.
- Composite Signal Score: Thermo Fisher Scientific 76/100 vs Rose BioSolutions 63/100 — a 13-point gap reflecting the combined quality, capacity and financial signal.
On a 13-modality CDMO landscape, both Rose BioSolutions and Thermo Fisher Scientific qualify as AAV manufacturers; Thermo Fisher Scientific carries the higher composite Signal Score for AAV programs in this comparison.
What to evaluate for AAV programs
Both Rose BioSolutions and Thermo Fisher Scientific qualify as AAV CDMOs. When choosing between them for AAV programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.
Platform & scale
Suspension processes scale better than adherent (HEK293) for commercial volumes. Confirm the CDMO's largest validated bioreactor scale and serotype track record.
Capsid quality
Full/empty capsid ratio and aggregate control drive potency and safety. Ask about AUC, anion-exchange separation, and the analytics package for capsid characterization.
Regulatory readiness
For programs heading to BLA, a strong FDA inspection history and EMA/MHRA GMP coverage matter — both are shown above and on each profile.
Capacity & timelines
AAV manufacturing slots can be constrained. Weigh the capacity signal and clinical-program load before committing.
Frequently asked: Rose BioSolutions vs Thermo Fisher Scientific
How does Rose BioSolutions compare to Thermo Fisher Scientific for AAV manufacturing?
On CDMO Signal's composite Signal Score, Rose BioSolutions is 63/100 and Thermo Fisher Scientific is 76/100; Rose BioSolutions has 0 FDA inspections on record vs 19 for Thermo Fisher Scientific; European coverage is 0 active EMA+MHRA certificates for Rose BioSolutions vs 10 for Thermo Fisher Scientific. Both are tracked in the CDMO Signal directory as AAV CDMOs. The scorecard above breaks down every metric side by side — use it alongside each CDMO's individual profile for the full regulatory and clinical footprint.
Which has the stronger FDA inspection record, Rose BioSolutions or Thermo Fisher Scientific?
Both Rose BioSolutions and Thermo Fisher Scientific maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. Rose BioSolutions has 0 FDA inspections on record; Thermo Fisher Scientific has 19.
How do Rose BioSolutions and Thermo Fisher Scientific compare on European GMP coverage?
Rose BioSolutions holds 0 active EMA GMP certificates and 0 MHRA / UK certificates. Thermo Fisher Scientific holds 1 active EMA GMP certificate and 9 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.
Which is more active in clinical-stage manufacturing — Rose BioSolutions or Thermo Fisher Scientific?
Rose BioSolutions is matched to 0 ClinicalTrials.gov records as a manufacturing partner; Thermo Fisher Scientific is matched to 2. Higher counts indicate broader sponsor exposure but say nothing about approved-product track record — pair this number with each CDMO's profile page for context.
Which is better for AAV manufacturing — Rose BioSolutions or Thermo Fisher Scientific?
Both Rose BioSolutions and Thermo Fisher Scientific are tagged as AAV CDMOs in our directory, so both are credible options for AAV programs. The most important differentiator for AAV selection is typically platform & scale: Suspension processes scale better than adherent (HEK293) for commercial volumes. Confirm the CDMO's largest validated bioreactor scale and serotype track record. Review each CDMO's profile and inspection record before shortlisting.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →